Hypothesis

Chronic insufficiency of CDP‑choline‑derived phosphatidylcholine impairs mitochondrial inner‑membrane cardiolipin composition, shifting lipid signaling toward ceramide accumulation and driving synapse elimination. This lipid‑mediated mechanism explains why low blood choline predicts faster brain aging and neurodegeneration, especially in obesity where inflammation suppresses CTP:phosphocholine cytidylyltransferase (CT) activity.

Mechanistic Rationale

1. CDP‑choline pathway and mitochondrial phospholipids – The CDP‑choline (Kennedy) route supplies phosphatidylcholine for mitochondrial membranes. When choline transport falls after age 55 (3), newly synthesized phosphatidylcholine drops, forcing mitochondria to remodel cardiolipin via phospholipid exchange.
2. Cardiolipin peroxidation and ceramide generation – Altered cardiolipin increases susceptibility to ROS‑mediated peroxidation, activating phospholipase D and sphingomyelinase pathways that generate ceramide (5). Ceramide‑rich microdomains promote Bax oligomerization and mitochondrial outer‑membrane permeabilization, triggering local synaptic degeneration.
3. Obesity‑linked inflammation – Adipose‑derived TNF‑α and IL‑6 suppress CT enzyme activity, further limiting phosphatidylcholine synthesis despite normal or elevated plasma choline (1). This creates a brain‑specific choline deficit that is not captured by blood measures.
4. Interaction with SIRT1 and one‑carbon metabolism – Adequate phosphatidylcholine supports SIRT1 deacetylation of PGC‑1α, enhancing mitochondrial biogenesis. Low choline reduces SAM‑dependent methylation, raising homocysteine, which exacerbates ceramide synthesis (4).

Together, these steps form a testable cascade: low CDP‑choline flux → abnormal mitochondrial phospholipid composition → ceramide‑driven synaptic loss → cognitive decline.

Testable Predictions

• In older adults with obesity and low plasma choline, mitochondrial isolates from post‑mortem temporal cortex will show decreased phosphatidylcholine‑to‑cardiolipin ratio and elevated ceramide species compared with lean controls.
• Acute CDP‑choline supplementation (500 mg daily for 12 weeks) will restore the phosphatidylcholine‑cardiolipin ratio in peripheral blood mononuclear cell mitochondria and concomitantly reduce plasma ceramide‑1‑phosphate levels.
• The metabolic rescue will correlate with improved episodic memory scores and reduced neurofilament light chain (NfL) only in participants who also exhibit increased SIRT1 activity (measured by deacetylated PGC‑1α).
• In APOE4 carriers, the same supplementation will produce a smaller lipid correction unless combined with a SIRT1 activator (e.g., resveratrol 500 mg), supporting a synergistic requirement.

Experimental Design

A double‑blind, placebo‑controlled 2 × 2 factorial trial (n = 200) stratified by BMI (≥30 vs <30) and APOE4 status. Arms: placebo, CDP‑choline alone, SIRT1 activator alone, CDP‑choline + SIRT1 activator. Primary outcome: change in mitochondrial phosphatidylcholine‑cardiolipin ratio isolated from PBMCs at baseline and week 12. Secondary outcomes: plasma ceramide panels, CSF NfL, composite memory score (ADAS‑Cog‑13), and SIRT1 activity (Western blot for acetyl‑PGC‑1α). Exploratory endpoint: PET‑measured synaptic vesicle glycoprotein 2A (SV2A) binding in a subset.

Potential Implications

If confirmed, the hypothesis reframes choline not merely as a precursor for acetylcholine but as a gatekeeper of mitochondrial lipid homeostasis that gates synaptic survival. It suggests that precision choline‑based nutraceuticals, combined with mitochondrial‑targeted SIRT1 modulation, could prevent or slow synaptotoxic cascades in obesity‑related Alzheimer risk, addressing the causality gap highlighted in current literature (6).